VivoSeq
Metabolic & Endocrine

Diabetes Mellitus

243

Pipeline Programs↗

40

Active Trials↗

78

Companies Involved↗

Diabetes Mellitus is a highly competitive landscape with 243 programs across 78 companies. The most active players are Daiichi Sankyo, Kiniksa Pharmaceuticals (UK), Ltd., Astellas. 85 therapies are approved with 62 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

83/100

Pipeline Velocity

42/100

Mech. Concentration

6/100

Completion Rate

86/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 1K

Kiniksa Pharmaceuticals (UK), Ltd.

1 program

Phase 1Astellas logo

Astellas

2 programs

Phase 1R

Repros Therapeutics Inc.

1 program

Phase 2Sun Pharmaceutical Industries Limited logo

Sun Pharmaceutical Industries Limited

1 program

Phase 2P

Pila Pharma

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

247 of 267 classified programs — the dominant modality here.

7%ALL OTHERSPeptide114%Monoclonal antibody83%Protein / enzyme1<1%

Small molecule leads; the ring shows all 267 classified programs, each share of the total. Modality classified for 99% of 287 pipeline programs.

Analysis

Trial Status

250

clinical trials

Completed148 · 59%
Unknown status37 · 15%
Recruiting22 · 9%
Terminated14 · 6%
Withdrawn10 · 4%
Not yet recruiting9 · 4%
Other10 · 4%

Clinical Trials

Trial Activity

250 trials

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
Recruiting·MMedanta, The Medicity, India·N/A·NCT06095492·200 enrolled
Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus
Recruiting·MMedanta, The Medicity, India·N/A·NCT06060392·50 enrolled
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
Recruiting·MMayo Clinic·Phase 2·NCT03865290·150 enrolled
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
Recruiting·Sun Pharmaceutical Industries Limited logoSun Pharmaceutical Industries Limited·Phase 2·NCT07282743·285 enrolled
Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus
Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 2·NCT06886126·240 enrolled
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
Recruiting·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 2·NCT07205900·250 enrolled
Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
Recruiting·—·Phase 4·NCT06706791·156 enrolled
Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus
Recruiting·GGuangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.·Phase 2·NCT06532578·240 enrolled
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT05838287·78 enrolled
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
Recruiting·EEMS·Phase 3·NCT05028140·480 enrolled
Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
Recruiting·CConsorcio Centro de Investigación Biomédica en Red (CIBER)·Phase 3·NCT05769868·1,000 enrolled
Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
Recruiting·EEMS·Phase 3·NCT04670666·270 enrolled
Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus
Recruiting·KKorea University Anam Hospital·Phase 4·NCT06767774·2,000 enrolled
SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus
Recruiting·—·Phase 4·NCT06364930·412 enrolled
Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus
Recruiting·AAzienda Ospedaliero-Universitaria di Parma·N/A·NCT05662189·70 enrolled
Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)